Skip to main content
. 2022 Nov 11;75(2):242–252. doi: 10.1002/art.42391

Figure 4.

Figure 4

Mean change in laboratory parameters over 48‐week follow‐up in patient groups receiving deucravacitinib 3 mg twice daily (BID), deucravacitinib 6 mg twice daily, deucravacitinib 12 mg once daily (QD), or placebo for treatment of systemic lupus erythematosus. Vertical bars represent standard deviations. ALT = alanine aminotransferase. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.42391/abstract.